Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deracoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deracoxib SCHEMBL24645 | 0.95 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL29593653 | 0.95 | PTGS2 (1.00) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL28723602 | 0.94 | PTGS2 (0.98) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL6601340 | 0.94 | PTGS2 (0.98) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL6343102 | 0.87 | PTGS2 (0.84) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL6341965 | 0.86 | PTGS2 (0.83) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL6818955 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL6349615 | 0.85 | PTGS2 (0.81) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL6909431 | 0.85 | PTGS2 (0.80) | PTGS2PTGS1ABCB11ALDH1A1 | |
| Deracoxib SCHEMBL6598846 | 0.84 | PTGS2 (0.79) | PTGS2PTGS1ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |